Australian Study: Teen Closed-Loop Pumps Help, But Support Gaps Remain

Australian Study: Teen Closed-Loop Pumps Help, But Support Gaps Remain

A study from Australia examined how young people with poorly controlled type 1 diabetes (T1D) experienced advanced hybrid closed-loop (AHCL) insulin pump therapy — and the findings offer important lessons for American families navigating the same technology.

What Is Advanced Hybrid Closed-Loop Therapy?

AHCL systems — sometimes called "artificial pancreas" technology — automatically adjust insulin delivery based on continuous glucose monitor (CGM) readings. The Medtronic MiniMed™ system used in this study is also commercially available in the United States, making these findings directly relevant to American patients.

What the Australian Researchers Found

Conducted at the Children's Diabetes Centre, Telethon Kids Institute at the University of Western Australia in Perth, this study focused on a group often overlooked in diabetes tech research: teenagers and young adults (ages 12–25) with high HbA1c levels. Participants entered the 6-month clinical trial with a mean HbA1c of 10.2% (average blood glucose of approximately 246 mg/dL), well above the American Diabetes Association's recommended target of under 7.0% (roughly 154 mg/dL) for most youth with T1D.

After six months on AHCL therapy, all ten participants reported improved glucose levels — a meaningful win. But the qualitative interviews revealed a more complicated picture, organized around three key themes:

• Improved blood sugar, even without using the system fully: Teens acknowledged their glucose improved, but most admitted they weren't using the closed-loop features optimally — skipping meal announcements, ignoring alerts, or frequently overriding the system.
• Persistent diabetes burden: Despite better numbers, participants still reported significant emotional exhaustion, frustration, and burnout related to daily diabetes management.
• A need for more psychosocial and clinical support: Participants consistently expressed that technology alone wasn't enough — they needed ongoing encouragement from family members and healthcare providers, as well as mental health resources.

Why This Matters for US Patients

In the United States, AHCL systems like the Medtronic MiniMed 780G and Tandem Control-IQ are increasingly prescribed to teenagers with difficult-to-control T1D. Yet this Australian research highlights a critical gap in how we support young users: access to the device is only half the battle.

American insurance and clinical systems often focus on getting the technology approved and delivered — but may underinvest in the psychological coaching, family education, and follow-up support that help teens actually use these systems well. The ADA's 2024 Standards of Care recommend psychosocial screening for all youth with T1D, yet many US practices lack dedicated diabetes mental health resources.

For American parents, this study is a reminder to ask your child's endocrinologist not just "Is my teen's A1c improving?" but also "How are they feeling about managing their diabetes?" and "What mental health or behavioral support is available to us?"

The Bottom Line

Advanced closed-loop pumps can meaningfully improve blood sugar in high-risk teens — even when used imperfectly. But without addressing diabetes distress and building a robust support network, the full potential of this life-changing technology may go unrealized.

Source: Roberts, Dart, Lloyd. "I Think I Could Have Used It Better": Experiences of Youth with High HbA1c Commencing Advanced Hybrid Closed-Loop Therapy in a Clinical Trial Setting. Pediatric Diabetes, 2024. DOI: 10.1155/2024/6260002. PMID: 40302968.